Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue: +64.0%
EPS: +525.8%
Free cash flow: +161.0%

Quarter to September 2026, against a year earlier

72.63 1.00 +1.40%

Follow CORT

Alert me

Market cap: $7.8B
P/E: 47.8×
Fwd P/E: 39.8×
Dividend yield: —
F-score: 4/9
Altman Z: 14.11
Beneish M: −2.76
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Corcept Therapeutics Incorporated 8-K filed May 28, 2026

Period ended May 21, 2026 · Filed May 28, 2026 · accepted 4:04 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov

Corcept Therapeutics Incorporated 8-K filed May 28, 2026

Stockrow Weekly